Dong-A ST Presents Poster on New Drug Candidate 'DA-1726' at US ADA

[Asia Economy Reporter Lee Gwan-joo] Dong-A ST announced on the 10th that it presented the preclinical research results of its new drug candidate 'DA-1726' in a poster session at the American Diabetes Association (ADA) conference.

DA-1726 is a new drug candidate under development as an obesity and diabetes treatment in the oxyntomodulin analogue class. It acts simultaneously on GLP-1 receptors and glucagon receptors to suppress appetite, promote insulin secretion, and increase basal metabolic rate in peripheral tissues, ultimately inducing weight loss and blood glucose control.

Dong-A ST confirmed superior weight loss effects of DA-1726 compared to the GLP-1 analogue semaglutide in obese animal models, and observed improvements in indicators related to energy metabolism.

Additionally, preclinical results on DA-1726’s treatment of non-alcoholic steatohepatitis (NASH) were also presented. The drug showed efficacy in improving NAS (NAFLD activity score), liver fibrosis, hepatotoxicity markers, and metabolic indicators, which are used as criteria for measuring treatment effects.

A Dong-A ST representative stated, “DA-1726 has balanced activity on GLP-1 and glucagon receptors, so it is expected to effectively regulate both weight and blood glucose simultaneously. These results also confirm the potential for treating NASH in addition to obesity and type 2 diabetes.”